Study on Synthesis and Biological Evaluation of 3-Aryl Substituted Xanthone Derivatives as Novel and Potent Tyrosinase Inhibitors. 2019

Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University.

Tyrosinase plays a key role in the melanin biosynthesis since it catalyzes the transformation of tyrosine into L-dopaquinone. A large number of studies have also shown that molecules to efficiently inhibit the activity of tyrosinase would be potentially used in treating many depigmentation-related disorders. In this study, we targeted a series of structure-based 3-aryl substituted xanthone derivatives in which diverse functional groups were respectively attached on 3-aromatic ring moiety as new tyrosinase inhibitors. The results demonstrated that all obtained compounds had potent tyrosinase inhibitory activities with IC50 values at micromolar range. Especially, compound 4t was found to be the most active tyrosinase inhibitor with the IC50 value of 11.3 µM, uncovering that the introduction of the proper hydroxyl group in the 3-aromatic ring was beneficial for enhancing the inhibitory potency against tyrosinase. Moreover, the inhibition mechanism and inhibition kinetics studies revealed that compound 4t presented such inhibitory effect by acting as the reversible and competitive-uncompetitive mixed-II type inhibitor. Further molecular docking simulation showed that 3-aromatic ring of compound 4t was inserted into the narrow regions of binuclear copper-binding site at the bottom of the enzyme binding pocket, while the xanthone skeleton was positioned at the surface of tyrosinase. Taken together, these data suggested that such type of molecules might be utilized for the development of new and promising candidate for the treatment of depigmentation-related disorders.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014442 Monophenol Monooxygenase An enzyme of the oxidoreductase class that catalyzes the reaction between L-tyrosine, L-dopa, and oxygen to yield L-dopa, dopaquinone, and water. It is a copper protein that acts also on catechols, catalyzing some of the same reactions as CATECHOL OXIDASE. EC 1.14.18.1. Dopa Oxidase,Phenoloxidase,Tyrosinase,Cresolase,Phenol Oxidase,Phenoloxidase A,Phenoloxidase B,Monooxygenase, Monophenol,Oxidase, Dopa,Oxidase, Phenol
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D044004 Xanthones A group of XANTHENES that contain a 9-keto OXYGEN. Xanthone Derivatives,Derivatives, Xanthone

Related Publications

Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
March 2012, Bioorganic & medicinal chemistry letters,
Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
May 2018, Bioorganic & medicinal chemistry,
Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
October 2014, European journal of medicinal chemistry,
Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
February 2010, European journal of medicinal chemistry,
Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
June 2009, Bioorganic & medicinal chemistry letters,
Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
January 2024, Bioorganic & medicinal chemistry letters,
Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
February 2012, Biochimie,
Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
September 2021, BMC chemistry,
Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
January 2015, Chemical & pharmaceutical bulletin,
Lihong Yu, and Liandi Chen, and Guolin Luo, and Licai Liu, and Wenqi Zhu, and Pengke Yan, and Peiquan Zhang, and Chao Zhang, and Wenhao Wu
November 2015, Chemical biology & drug design,
Copied contents to your clipboard!